Orphan Drug Access Threatened By Medicaid Transformation, NORD Says
Executive Summary
National Organization for Rare Disorders raises concerns with proposals to limit US federal financial contributions and coverage requirements in Medicaid programs, maintaining states could limit access to orphan drugs.
You may also be interested in...
Medicaid Drug Formulary Ideas Floated, But US Manufacturers Are Skeptical
Medicaid formularies capable of excluding drugs to drive better rebates could replace the existing drug rebate program, lobbyists suggest, but US manufacturers worry that lawmakers will be leery of losing statutory-based rebates.
US Medicaid Reform: Legislators Caution CMS Nominee About Coverage Loss
Seema Verma is closely identified with Medicaid reform but both Republicans and Democrats expressed concern during her Senate confirmation hearing that reforms not translate into loss of insurance coverage.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.